NCT05406505View on ClinicalTrials.gov

Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

May 1, 2023

Study Completion Date

July 1, 2023

Conditions
Acute Heart Failure
Interventions
DRUG

Dapagliflozin 10mg Tab

patients will receive once daily dapagliflozin 10 mg orally in addition to standard care

OTHER

Placebo

patients will receive placebo and standard care.

Trial Locations (1)

35516

Noha Mansour, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER